XPEL vs. CPRX

In the year-to-date period, XPEL achieves a -31.40% return, which is significantly lower than CPRX's 11.12% return. Over the past 10 years, XPEL has outperformed CPRX with an annualized return of 27.06%, while CPRX has yielded a comparatively lower 21.40% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for XPEL, Inc. (XPEL) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current XPEL Sharpe Ratio is -0.63, which is lower than the CPRX Sharpe Ratio of 1.29. The chart below compares the historical Sharpe Ratios of XPEL and CPRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither XPEL nor CPRX has paid dividends to shareholders.

The maximum XPEL drawdown since its inception was -99.77%, which is greater than CPRX's maximum drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for XPEL and CPRX. For additional features, visit the drawdowns tool.

XPEL, Inc. (XPEL) has a higher volatility of 20.69% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 14.57%. This indicates that XPEL's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between XPEL, Inc. and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.